Image source: GETTY IMAGES
Image source: GETTY IMAGES

Moderna has recruited its first participants in the first phase of clinical trial testing MRNA-1273, its vaccine is against the novel coronavirus that causes COVID-19.

The move brings biotech one step closer to possibly the first COVID-19 vaccine available in the United States, although this time is not surprising. Moderna announced plans to begin mid-term studies in April. Followed by approval from the Food and Drug Administration last month. And the first phase of vaccine data released on May 18 certainly looked promising enough to justify mid-stage testing.

Image source: GETTY IMAGES

(A syringe and a hand attached to a person’s shoulder: defective images.)

The Moderna study aims to include 600 participants, half of whom are 55 years of age or older. Based on the first phase of the study, Moderna intends to test two doses of the drug, which will be compared to a placebo. Each participant will receive a booster to increase early vaccination and antibody production.

Phase 2 Clinical Trial 45 Participants can read faster than a Phase 1 study that took about two months to collect data. This is because all participants can be eliminated immediately, in contrast to a Phase 1 dose increase study. where safety data from each dose has to be collected before the next dose begins.

Sure, there are a lot more participants in the Phase 2 study, but finding 600 people interested in enrolling in this study shouldn’t be too difficult. Everything being done is just because of COVID-19. COVID-19 has affected the world more than any other pandemic disease.

Moderna is shooting to begin the Phase 3 clinical trial in July. The company is still working on the design of the study

, but it may require thousands of participants to submit safety data so that the vaccine can be approved on a regular basis.

10 stocks that make us better than Moderna INC

When David and Tom Gardner’s intelligence investment is a stock tip, it pays to listen. However, in a newsletter he has run for over a decade, Motley Fool Stock Advisors has tripled the market. *

David and Tom have just revealed that they believe they are the top ten stocks for investors to buy right now; and Moderna INC was not one of them! That’s fine – this is a 10 buck, even better.

That stock could be the equivalent of buying Amazon in 1997

Imagine if you bought Amazon in 1997; a investment $5,000 investment would be worth more than $4 million today.

You can’t go back to Amazon 20 years ago; but what our analysts think might be the next best thing: a special stock of amazing growth potential in mind.

Already with hundreds of thousands of business users signing up, the stock has been dubbed the “amazing match like the early”

Please follow and like us:
Pin Share

By Saif

I'm not a blogger by profession. But Blogging is my passion.

Leave a Reply

Your email address will not be published. Required fields are marked *